Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy

Yohei Ikezumi, Toshiaki Suzuki, Tamaki Karasawa, Hiroshi Kawachi, David J. Nikolic-Paterson, Makoto Uchiyama

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). In this study, we evaluated the efficacy of Miz treatment in three children with established steroid-resistant IgAN. The patients had IgAN featuring persistent proteinuria and diffuse mesangial proliferation and had failed to respond to 2 years of treatment with prednisolone. Based upon the second biopsy results, patients were given methylprednisolone (mPSL) pulse therapy that induced a transient reduction in proteinuria, which was reversed when the mPSL dose was tapered. Miz therapy was then instigated in place of pulse mPSL. All three patients showed a substantial reduction in proteinuria and resolution of hematuria within 5 months. A follow-up biopsy in two of the patients showed a substantial reduction in the severity of glomerular lesions and a decrease in the number of activated macrophages. In conclusion, Miz therapy was found to be a safe and effective therapy in three cases of steroid-resistant pediatric IgAN. The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients.

Original languageEnglish
Pages (from-to)645-650
Number of pages6
JournalPediatric Nephrology
Volume23
Issue number4
DOIs
Publication statusPublished - 01-04-2008

Fingerprint

Drug Repositioning
Immunoglobulin A
Steroids
Pediatrics
Methylprednisolone
Proteinuria
Therapeutics
Macrophages
Biopsy
Hematuria
Immunosuppressive Agents
Prednisolone
Pharmaceutical Preparations
bredinin
Clinical Trials
Kidney

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Ikezumi, Y., Suzuki, T., Karasawa, T., Kawachi, H., Nikolic-Paterson, D. J., & Uchiyama, M. (2008). Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. Pediatric Nephrology, 23(4), 645-650. https://doi.org/10.1007/s00467-007-0664-2
Ikezumi, Yohei ; Suzuki, Toshiaki ; Karasawa, Tamaki ; Kawachi, Hiroshi ; Nikolic-Paterson, David J. ; Uchiyama, Makoto. / Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. In: Pediatric Nephrology. 2008 ; Vol. 23, No. 4. pp. 645-650.
@article{983ca62e859a4a08a565949a31b863c9,
title = "Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy",
abstract = "Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). In this study, we evaluated the efficacy of Miz treatment in three children with established steroid-resistant IgAN. The patients had IgAN featuring persistent proteinuria and diffuse mesangial proliferation and had failed to respond to 2 years of treatment with prednisolone. Based upon the second biopsy results, patients were given methylprednisolone (mPSL) pulse therapy that induced a transient reduction in proteinuria, which was reversed when the mPSL dose was tapered. Miz therapy was then instigated in place of pulse mPSL. All three patients showed a substantial reduction in proteinuria and resolution of hematuria within 5 months. A follow-up biopsy in two of the patients showed a substantial reduction in the severity of glomerular lesions and a decrease in the number of activated macrophages. In conclusion, Miz therapy was found to be a safe and effective therapy in three cases of steroid-resistant pediatric IgAN. The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients.",
author = "Yohei Ikezumi and Toshiaki Suzuki and Tamaki Karasawa and Hiroshi Kawachi and Nikolic-Paterson, {David J.} and Makoto Uchiyama",
year = "2008",
month = "4",
day = "1",
doi = "10.1007/s00467-007-0664-2",
language = "English",
volume = "23",
pages = "645--650",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "4",

}

Ikezumi, Y, Suzuki, T, Karasawa, T, Kawachi, H, Nikolic-Paterson, DJ & Uchiyama, M 2008, 'Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy', Pediatric Nephrology, vol. 23, no. 4, pp. 645-650. https://doi.org/10.1007/s00467-007-0664-2

Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. / Ikezumi, Yohei; Suzuki, Toshiaki; Karasawa, Tamaki; Kawachi, Hiroshi; Nikolic-Paterson, David J.; Uchiyama, Makoto.

In: Pediatric Nephrology, Vol. 23, No. 4, 01.04.2008, p. 645-650.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy

AU - Ikezumi, Yohei

AU - Suzuki, Toshiaki

AU - Karasawa, Tamaki

AU - Kawachi, Hiroshi

AU - Nikolic-Paterson, David J.

AU - Uchiyama, Makoto

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). In this study, we evaluated the efficacy of Miz treatment in three children with established steroid-resistant IgAN. The patients had IgAN featuring persistent proteinuria and diffuse mesangial proliferation and had failed to respond to 2 years of treatment with prednisolone. Based upon the second biopsy results, patients were given methylprednisolone (mPSL) pulse therapy that induced a transient reduction in proteinuria, which was reversed when the mPSL dose was tapered. Miz therapy was then instigated in place of pulse mPSL. All three patients showed a substantial reduction in proteinuria and resolution of hematuria within 5 months. A follow-up biopsy in two of the patients showed a substantial reduction in the severity of glomerular lesions and a decrease in the number of activated macrophages. In conclusion, Miz therapy was found to be a safe and effective therapy in three cases of steroid-resistant pediatric IgAN. The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients.

AB - Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). In this study, we evaluated the efficacy of Miz treatment in three children with established steroid-resistant IgAN. The patients had IgAN featuring persistent proteinuria and diffuse mesangial proliferation and had failed to respond to 2 years of treatment with prednisolone. Based upon the second biopsy results, patients were given methylprednisolone (mPSL) pulse therapy that induced a transient reduction in proteinuria, which was reversed when the mPSL dose was tapered. Miz therapy was then instigated in place of pulse mPSL. All three patients showed a substantial reduction in proteinuria and resolution of hematuria within 5 months. A follow-up biopsy in two of the patients showed a substantial reduction in the severity of glomerular lesions and a decrease in the number of activated macrophages. In conclusion, Miz therapy was found to be a safe and effective therapy in three cases of steroid-resistant pediatric IgAN. The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients.

UR - http://www.scopus.com/inward/record.url?scp=40549102494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549102494&partnerID=8YFLogxK

U2 - 10.1007/s00467-007-0664-2

DO - 10.1007/s00467-007-0664-2

M3 - Article

C2 - 18038158

AN - SCOPUS:40549102494

VL - 23

SP - 645

EP - 650

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 4

ER -